Verdiva Bio presents preclinical data on obesity treatments
Verdiva Bio has announced new preclinical data for VRB-103, a once-weekly oral amylin receptor-selective amylin analog, and VRB-104, a unimolecular amylin and GLP-1 receptor dual agonist.
The data were presented in poster sessions at the American Diabetes Association (ADA), taking place 5-8 June in New Orleans, Louisiana, US.
Amylin is a peptide hormone that reduces appetite, delays gastric emptying, and decreases glucagon release. It functions by activating human amylin receptors (hAMY1R, hAMY2R and hAMY3R), which consist of the calcitonin receptor (hCTR) in complex with receptor activity modifying proteins (RAMP1-3).
VRB-103 is currently in preclinical development as a once-weekly oral tablet for obesity and is expected to enter the clinic in H2 2026 as both a monotherapy and in combination with VRB-101, a once-weekly oral GLP-1 analog currently in Phase II development.
In the first study, VRB-103 exhibited greater potency than eloralintide and cagrilintide across all three human amylin receptor subtypes. When normalised to cagrilintide, VRB‑103 demonstrated greater relative activation of amylin receptors compared with the calcitonin receptor.
Combination of GLP-1 and amylin receptor agonists has demonstrated greater weight loss and glycemic control than either agent alone. VRB-104 is a novel unimolecular amylin and GLP-1 receptor dual agonist and has demonstrated selectivity for hAMY3R over GLP-1R.
In cell culture, VRB-104 demonstrated nearly three-fold increased potency on hAMY3R and nine-fold reduced potency on GLP-1R, when compared to amycretin. In a diet-induced obesity model, daily dosing of VRB-104 for 14 days resulted in 14% body weight loss from baseline.
“This preclinical data highlights the breadth of Verdiva Bio’s portfolio and the potential to develop differentiated medicines for diverse patient groups,” said Dr Jane Hughes, President R&D at Verdiva Bio. “We look forward to advancing the development of these next-generation medicines for people living with obesity.”
